Essential Thrombocythemia - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 86 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Essential Thrombocythemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Essential Thrombocythemia - Pipeline Review, H2 2014', provides an overview of the Essential Thrombocythemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Essential Thrombocythemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Essential Thrombocythemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Essential Thrombocythemia Overview 7
Therapeutics Development 8
Pipeline Products for Essential Thrombocythemia - Overview 8
Pipeline Products for Essential Thrombocythemia - Comparative Analysis 9
Essential Thrombocythemia - Therapeutics under Development by Companies 10
Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes 11
Essential Thrombocythemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Essential Thrombocythemia - Products under Development by Companies 15
Essential Thrombocythemia - Products under Investigation by Universities/Institutes 16
Essential Thrombocythemia - Companies Involved in Therapeutics Development 17
AstraZeneca PLC 17
Eli Lilly and Company 18
Shire Plc 19
Incyte Corporation 20
Galena Biopharma, Inc. 21
Italfarmaco S.p.A. 22
Promedior, Inc. 23
Onconova Therapeutics, Inc. 24
Pharma Mar, S.A. 25
Essential Thrombocythemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
anagrelide hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ruxolitinib phosphate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PRM-151 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
plitidepsin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
givinostat - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
gandotinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
anagrelide hydrochloride CR - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AZD-1480 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
rigosertib sodium - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Essential Thrombocythemia - Recent Pipeline Updates 56
Essential Thrombocythemia - Dormant Projects 73
Essential Thrombocythemia - Discontinued Products 74
Essential Thrombocythemia - Product Development Milestones 75
Featured News & Press Releases 75
Mar 12, 2014: Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma 75
Jun 16, 2013: Geron Announces Presentation Of Updated Results From Imetelstat Phase II Trial In Essential Thrombocythemia At 18th EHA Congress 75
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 77
Dec 10, 2012: Geron Presents Positive Results From Phase II Study Of Imetelstat In Essential Thrombocythemia At ASH Annual Meeting 78
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 79
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 80
Mar 03, 2010: Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting 81
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 84
Apr 18, 2005: IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005 84
Apr 18, 2005: Mylan Receives Approval for Anagrelide Hydrochloride Capsules 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
Number of Products under Development for Essential Thrombocythemia, H2 2014 8
Number of Products under Development for Essential Thrombocythemia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Essential Thrombocythemia - Pipeline by AstraZeneca PLC, H2 2014 17
Essential Thrombocythemia - Pipeline by Eli Lilly and Company, H2 2014 18
Essential Thrombocythemia - Pipeline by Shire Plc, H2 2014 19
Essential Thrombocythemia - Pipeline by Incyte Corporation, H2 2014 20
Essential Thrombocythemia - Pipeline by Galena Biopharma, Inc., H2 2014 21
Essential Thrombocythemia - Pipeline by Italfarmaco S.p.A., H2 2014 22
Essential Thrombocythemia - Pipeline by Promedior, Inc., H2 2014 23
Essential Thrombocythemia - Pipeline by Onconova Therapeutics, Inc., H2 2014 24
Essential Thrombocythemia - Pipeline by Pharma Mar, S.A., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Essential Thrombocythemia Therapeutics - Recent Pipeline Updates, H2 2014 56
Essential Thrombocythemia - Dormant Projects, H2 2014 73
Essential Thrombocythemia - Discontinued Products, H2 2014 74